OLANZAPINE

Post-LOE

olanzapine

ANDAINTRAMUSCULARPOWDER
Approved
Mar 2026
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism. 12.2 Pharmacodynamics Olanzapine binds with high…

Pharmacologic Class:

Atypical Antipsychotic

Clinical Trials (5)

NCT06649214Phase 3Not Yet Recruiting

A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

Started Nov 2024
NCT05705492Phase 2Recruiting

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Started Jul 2024
66 enrolled
Advanced Malignant Solid NeoplasmAdvanced Biliary Tract CarcinomaAdvanced Esophageal Carcinoma+7 more
NCT06319170Phase 1Completed

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Started Mar 2024
106 enrolled
Schizophrenia, Schizoaffective Disorder
NCT06315283Phase 1Completed

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Started Mar 2024
153 enrolled
Schizophrenia
NCT06600477Phase 1Completed

A Study of Olanzapine After Intranasal and Intramuscular Administration

Started Oct 2023
24 enrolled
Healthy